Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Moreno

Showing results (101-110 of 194) with videos related to

Pageof 20
Sort By:
Journal of Hepatology|February 22, 2011
Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver diseaseEric Trépo, Thierry Gustot, Delphine Degré, et al.
Journal of Hepatology|June 20, 2014
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access programMassimo Colombo, Simone Strasser, Christophe Moreno, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Gastro Hep Advances|February 25, 2025
Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier AlterationsAlia Hadefi, Morgane Leprovots, Gilles Dinsart, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2017
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir RegimenStefan Bourgeois, Yves Horsmans, Frederik Nevens, et al.
Journal of Hepatology|April 6, 2013
Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver diseaseEric Trépo, Romy Ouziel, Pierre Pradat, et al.
Plos One|September 24, 2015
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or CirrhosisAntonia Lepida, Massimo Colombo, Inmaculada Fernandez, et al.
Hepatology (Baltimore, Md.)|July 1, 2025
Antibody response to microbiota antigens is associated with alcohol-related liver disease severity and predicts mortalityAntonella Putignano, Natasha S Kelkar, Dalila Lakhloufi, et al.
Hepatology (Baltimore, Md.)|June 4, 2013
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is not associated with alcoholic liver disease severityAnne Lemaire, Eric Trépo, Romy Ouziel, et al.
Pageof 20

Showing results (101-110 of 194) with videos related to

Sort By:
Pageof 20
Journal of Hepatology|February 22, 2011
Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver diseaseEric Trépo, Thierry Gustot, Delphine Degré, et al.
Journal of Hepatology|June 20, 2014
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access programMassimo Colombo, Simone Strasser, Christophe Moreno, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Gastro Hep Advances|February 25, 2025
Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier AlterationsAlia Hadefi, Morgane Leprovots, Gilles Dinsart, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2017
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir RegimenStefan Bourgeois, Yves Horsmans, Frederik Nevens, et al.
Journal of Hepatology|April 6, 2013
Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver diseaseEric Trépo, Romy Ouziel, Pierre Pradat, et al.
Plos One|September 24, 2015
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or CirrhosisAntonia Lepida, Massimo Colombo, Inmaculada Fernandez, et al.
Hepatology (Baltimore, Md.)|July 1, 2025
Antibody response to microbiota antigens is associated with alcohol-related liver disease severity and predicts mortalityAntonella Putignano, Natasha S Kelkar, Dalila Lakhloufi, et al.
Hepatology (Baltimore, Md.)|June 4, 2013
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is not associated with alcoholic liver disease severityAnne Lemaire, Eric Trépo, Romy Ouziel, et al.
Pageof 20